These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 26932795)

  • 1. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry.
    Vallejo-Yagüe E; Burkard T; Finckh A; Burden AM;
    BMJ Open; 2024 Feb; 14(2):e074864. PubMed ID: 38331859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
    Bitoun S; Hässler S; Ternant D; Szely N; Gleizes A; Richez C; Soubrier M; Avouac J; Brocq O; Sellam J; de Vries N; Huizinga TWJ; Jury EC; Manson JJ; Mauri C; Matucci A; Hacein Bey Abina S; Mulleman D; Pallardy M; Broët P; Mariette X;
    JAMA Netw Open; 2023 Jul; 6(7):e2323098. PubMed ID: 37436748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
    Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body mass index and response to abatacept in rheumatoid arthritis.
    Gardette A; Ottaviani S; Sellam J; Berenbaum F; Lioté F; Fautrel B; Palazzo E; Meyer A; Sibilia J; Dieudé P
    Eur J Clin Invest; 2016 Dec; 46(12):1048-1052. PubMed ID: 27736006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
    Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
    Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study.
    Gardette A; Ottaviani S; Sellam J; Berenbaum F; Lioté F; Meyer A; Sibilia J; Fautrel B; Palazzo E; Dieudé P
    Clin Rheumatol; 2016 Apr; 35(4):857-61. PubMed ID: 26801332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study.
    Hirata S; Li W; Defranoux N; Cavet G; Bolce R; Yamaoka K; Saito K; Tanaka Y
    Mod Rheumatol; 2015 May; 25(3):344-9. PubMed ID: 25295918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
    Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
    Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
    Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
    Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study.
    Di Carlo M; Salaffi F; Gremese E; Iannone F; Lapadula G; Ferraccioli G;
    Eur J Intern Med; 2019 Aug; 66():57-61. PubMed ID: 31113709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.
    Feuchtenberger M; Kleinert S; Scharbatke EC; Gnann H; Behrens F; Wittig BM; Greger G; Tony HP
    Clin Exp Rheumatol; 2015; 33(3):321-9. PubMed ID: 25897681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
    Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.
    Jiménez Morales A; Maldonado-Montoro M; Martínez de la Plata JE; Pérez Ramírez C; Daddaoua A; Alarcón Payer C; Expósito Ruiz M; García Collado C
    J Clin Pharmacol; 2019 Apr; 59(4):517-531. PubMed ID: 30457672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.